Get the Stockscreener App
0.8831
3.19%
-0.0293
Heron Therapeutics Inc stock is traded at $0.8831, with a volume of 647.29K.
It is down -3.19% in the last 24 hours and down -7.67% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$0.9124
Open:
$0.93
24h Volume:
647.29K
Relative Volume:
0.30
Market Cap:
$167.13M
Revenue:
$154.90M
Net Income/Loss:
$-20.20M
P/E Ratio:
-7.3286
EPS:
-0.1205
Net Cash Flow:
$-27.91M
1W Performance:
-27.00%
1M Performance:
-7.67%
6M Performance:
-19.70%
1Y Performance:
-52.76%
1-Day Range:
$0.8758
$0.9343
1-Week Range:
$0.8758
$1.09
52-Week Range:
$0.7362
$2.30
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.883 | 173.08M | 154.90M | -20.20M | -27.91M | -0.1205 |
VRTX
Vertex Pharmaceuticals Inc
|
443.30 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
699.35 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.82 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
290.91 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.49 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN
Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative - Sahm
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com
TradingKey - TradingKey
Heron (HRTX) Q1 2026 Earnings Call Transcript - AOL.com
Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX - Moomoo
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus - Investing.com Canada
Heron Therapeutics Q1 earnings call highlights - MSN
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility - TipRanks
Heron Therapeutics 1Q Loss/Shr 4c >HRTX - Moomoo
Heron Therapeutics Signals Recovery Despite Soft Q1 - TipRanks
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Heron Therapeutics, Inc. Form 10-Q: Financial Results, Forward-Looking Statements, and Key Risks for Q1 2026 - Minichart
Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Heron Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 - marketscreener.com
Heron Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) reports Q1 loss, lags revenue estimates - MSN
Heron Therapeutics Q1 Earnings Call Highlights - MarketBeat
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline - Yahoo Finance
Heron Therapeutics Reports Q1 2026 Results: 32% Acute Care Revenue Growth, Reaffirms 2026 Guidance - Minichart
HRTX: Q1 sales reached $34.7M, rebounding in March, with strong growth and full-year guidance reaffirmed - TradingView
HRTX: Q1 sales hit $34.7M, acute care up 32% YoY, guidance reaffirmed, and commercial expansion planned - TradingView
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX - ChartMill
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Heron Therapeutics Q1 2026 earnings preview - MSN
Heron Therapeutics' Q1 revenue falls as oncology sales drop - TradingView
HERON THERAPEUTICS, INC. /DE/ 1Q 2026: Revenue $34.7M, EPS $(0.04) — 10-Q Summary - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - kare11.com
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance - The Manila Times
BRIEF-Heron Therapeutics Q1 EPS USD -0.04 - TradingView
Heron Therapeutics (HRTX) swings to Q1 2026 loss as oncology sales fall and interest costs rise - Stock Titan
[8-K] HERON THERAPEUTICS, INC. /DE/ Reports Material Event - Stock Titan
MSN Money - MSN
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Earnings Preview: HRTX to Report Financial Results Pre-market on May 11 - Moomoo
Heron Therapeutics (HRTX) COO acquires 125,000 shares via RSU exercise - Stock Titan
Analysts estimate Heron Therapeutics (HRTX) to report a decline in earnings: What to look out for - MSN
Heron Therapeutics (HRTX) COO gains 11,770 shares through RSU conversion - Stock Titan
Heron EVP exercises RSUs into 23,464 common shares | HRTX Insider Trading - Stock Titan
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):